Satellite Symposia

Friday, October 18
6:30 am – 8:00 am
Chicago VIII

Why Do We Need Dietary Therapy in Crohn’s Disease in an Era of Biologics?
Program Director: Robert N. Baldassano, MD
Colman Professor of Pediatrics, Children’s Hospital of Philadelphia

Why Do We Need Diet in an Era of Biologics?
Dr. Lindsey Albenberg
Children’s Hospital of Philadelphia, Philadelphia, PA
The need for alternatives to chronic immunosuppression as the prime treatment strategy in IBD is vital. Patients and families are concerned about drug safety and wish to manage their own IBD. Despite definite impact, the efficacy of current and novel biologics is limited in inducing and maintaining remission, and there are safety issues with long-term use. Given that gut luminal content is influenced by diet and drives inflammation, the evidence for therapeutic benefit with dietary therapy, and patients strong interest in dietary strategies, it is vital to include diet as part of the therapeutic strategy for IBD.

What Are the Targets for Dietary Therapy?
Dr. Arie Levine
Wolfson Medical Center, Tel Aviv, Israel
Recent evidence suggests that environmental factors and particularly diet may play a role in the pathogenesis of Crohn’s disease. Identification of these factors would open a window on to new therapeutic targets for treatment and prevention. By identifying plausible dietary components that negatively affect the microbiome, mucous layer and intestinal permeability; we were able to develop a novel well-tolerated diet that leads to equivalent remission rates, an identical decrease in inflammation and similar changes to the microbiome when compared with EEN in a randomized controlled trial.

Present State of the Art on Dietary Management in Crohn’s Disease
Dr. Eytan Wine
Edmonton Clinic Health Academy, Edmonton, Canada
There remains a gap between patient’s interest in diet in IBD and what we as health care providers can deliver. Exclusive enteral nutrition has been an exception to this, with good clinical data for induction of remission in pediatric Crohn’s disease, but recent studies offer exciting opportunities for innovation in dietary therapy.

The New Kid on the Block: The Crohn’s Disease Exclusion Diet for Induction of Remission
Rotem Sigall-Boneh, RD
Wolfson Medical Center, Tel Aviv, Israel
Diet has taken an important step forward with the adoption of EEN as a recommended first line therapy. This has led to a search for a more tolerable and feasible dietary approach for induction of remission. The existence of a novel dietary therapy comprised of a whole food diet coupled with 50% PEN will place diet and dietitians at the forefront of therapy of CD in the future.

Presented for attendees of the NASPGHAN Annual Meeting. This is not an official NASPGHAN event.

Financial support provided by Nestlé Health Science.

Nestlé Health Science is a Continuing Professional Education Accredited Provider with CDR, the credentialing agency for the Academy of Nutrition and Dietetics. Accredited provider number NE008. Nestlé Health Science is a Continuing Education Provider approved by the California Board of Registered Nursing; Provider Number 11366. 1.5 CPEUs available for dietitians and 1.5 contact hours available for nurses. There is no charge for participating in this program.

Saturday, October 19
6:30 am - 8:00 am 
Chicago VIII

A Clinical Overview and Application of Omega-3 Fatty Acid Containing Lipid Emulsions

Gordon Sacks 
Senior Director Medical Affairs 
Fresenius Kabi USA

This presentation will provide an overview of Omega-3 fatty acids in parenteral nutrition lipid emulsions for neonatal, pediatric and adult patients, as well as the clinical application of fish oil-containing lipid emulsions, for parenteral nutrition.

Supported by: Fresenius Kabi

To secure your seat at this presentation, please register at:

Friday, October 18
6:00pm - 10:00pm
Chicago X

Where Are We Now in the Management of Eosinophilic Esophagitis? Controversies and Catalysts

Program Director: Rod Smith, Scientific Director, Medscape

Program Agenda:
The goal of this activity is to update pediatric gastroenterologists on diagnosis, management, and emerging treatments for EoE.

Drs Hirano, Chehade and Gupta will engage in an interactive multi-format symposium, incorporating debate-style and Roundtable Panel Discussion presentation approaches, with a focus on the pediatric population. The following is the proposed content focus:


Assessment of participant baseline knowledge, competence, and confidence on EoE answered using iPads; this may include a pediatric case of EoE with questions on guideline-based care (eg, from diagnosis to management) 

Debating the pathogenesis of EoE

  • Is there variability between children and adults, race and gender?
  • Is EoE a progressive disease vs subtypes?
  • Can phenotypes be used to predict prognosis or therapeutic response?

Is diagnosis straightforward or are there still controversies?
  • Controversies related to PPI use and a discussion on updates in diagnostic criteria and steps for diagnosis, with a focus on the pediatric population

Headlines in EoE: A Roundtable Panel Discussion on the current and emerging management of EoE, which may include the role of
  • Dietary modifications
  • Clinical data on topical and systemic glucocorticoids
    • Emerging treatments, clinical trial design, and the latest clinical data
  • The role of various HCPs in diagnosis and management: from the pediatric gastroenterologist to the allergist/clinical immunologist

Posteducation assessment

Conclusions and Q&A

Learning Objectives:
Upon completion of this activity, learners will have

  • Increased knowledge regarding the
    • Pathogenesis of EoE
    • Clinical presentations of EoE in the pediatric population
    • Clinical data on emerging therapies for EoE
  • Greater competence related to
    • Incorporating the latest guidelines for diagnosis of EoE
A coordinated team approach to evidence-based management of patients with EoE

Supported by: Takeda Pharmaceutical Company Limited
Shire is now part of Takeda

Registration link:

Saturday, October 19
6:30am - 8:00am
Chicago X

Pediatric SBS Unplugged: Advances in Achieving Better Long-Term Outcomes

Program Director: Rod Smith, Scientific Director, Medscape

Program Agenda:
Pediatric short bowel syndrome (SBS) is a serious condition that without treatment is fatal in children. SBS continues to present diagnostic and management challenges for clinicians. In this live, interactive symposium, Drs Iyer and Cohran will use real patient cases to present their perspectives on the diagnosis and management of the condition, with a focus on novel treatments to improve intestinal adaptation and rehabilitation while managing risks and reducing long-term complications. The audience will have the opportunity to engage the faculty by submitting questions and participating in clinical decision making.

Learning Objectives:
Upon completion of this activity, learners will have:

  • Increased knowledge regarding the
    • Management goals for pediatric patients with SBS within the scope of the multidisciplinary team of healthcare providers
    • Strategies to reduce dependence on PN
    • Clinical data on pharmacotherapeutic options for pediatric SBS
  • Greater competence related to
    • Identifying pediatric patients who may benefit from new treatments for SBS
    • Managing short- and long-term complications of pediatric SBS
  • Greater confidence in their ability to communicate the risks and benefits of treatment options for pediatric SBS to parents

Supported by: Takeda Pharmaceutical Company Limited
Shire is now part of Takeda

Registration link: